Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2− Highly Proliferative Breast Cancer
Miguel Martín, Ángel Guerrero‐Zotano, Eva Pérez, Manuel Ruíz-Borrego et autres
PURPOSE: Neoadjuvant chemotherapy is standard for high-risk hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. This study evaluates whether 12 months of letrozole plus abemaciclib could be an alternative. PATIENTS AND METHODS: The phase II, open-label CARABELA trial …
es, us (code pays fourni par la source)